Campbell & CO Investment Adviser LLC Sells 23,356 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Campbell & CO Investment Adviser LLC reduced its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 51.0% in the 2nd quarter, HoldingsChannel reports. The fund owned 22,433 shares of the company’s stock after selling 23,356 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Amphastar Pharmaceuticals were worth $515,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Signaturefd LLC grew its stake in shares of Amphastar Pharmaceuticals by 147.7% in the first quarter. Signaturefd LLC now owns 872 shares of the company’s stock worth $25,000 after purchasing an additional 520 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in Amphastar Pharmaceuticals by 192.8% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company’s stock worth $29,000 after buying an additional 831 shares during the period. Hantz Financial Services Inc. grew its position in shares of Amphastar Pharmaceuticals by 3,430.8% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock valued at $32,000 after buying an additional 1,338 shares during the last quarter. IFP Advisors Inc acquired a new stake in shares of Amphastar Pharmaceuticals in the first quarter valued at about $34,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Amphastar Pharmaceuticals in the first quarter valued at about $39,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $26.06 on Friday. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The firm’s 50-day moving average price is $25.92 and its 200-day moving average price is $25.37. The firm has a market capitalization of $1.20 billion, a P/E ratio of 9.76 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a 1-year low of $20.39 and a 1-year high of $46.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.10. The business had revenue of $191.84 million for the quarter, compared to the consensus estimate of $186.90 million. Amphastar Pharmaceuticals had a return on equity of 20.76% and a net margin of 18.64%. Equities research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on AMPH. Bank of America lifted their price objective on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Needham & Company LLC reduced their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Weiss Ratings reissued a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, October 8th. Piper Sandler dropped their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a report on Friday, August 8th. Finally, Zacks Research upgraded Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.20.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.